Cart
sales@molnova.com
Pamrevlumab
CAS No. 946415-13-0
Pamrevlumab( —— )
Catalog No. M36727 CAS No. 946415-13-0
Pamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 392 | In Stock |
|
| 10MG | 629 | In Stock |
|
| 25MG | 938 | In Stock |
|
| 50MG | 1274 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePamrevlumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionPamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
-
DescriptionFG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number946415-13-0
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sgalla G, et, al. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2020 Aug;29(8):771-777.?
molnova catalog
related products
-
Forodesine
Forodesine (BCX-1777) is an orally active and potent purine nucleoside phosphorylase (PNP) inhibitor, a new purine nucleoside analog.
-
MitoBloCK-6
MitoBloCK-6 is a potent Erv1/ALR inhibitor with IC50 values of 900 nM and 700 nM, respectively, and also inhibits Erv2 with an IC50 of 1.4 μM.
-
BTT-3033
BTT-3033 is an orally active and potent α2β1 (EC50: 130 nM) inhibitor with an affinity for the α2I domain, inhibiting platelet binding to collagen I and cell proliferation.
